Pulmonx Corporation ( (LUNG) ) has released its Q3 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), known for its Zephyr Endobronchial Valve and other innovative solutions aimed at improving the quality of life for patients with severe emphysema.
In the third quarter of 2025, Pulmonx Corporation reported a 5% increase in worldwide revenue, reaching $21.5 million, driven by strong international growth and steady U.S. performance. The company also announced key executive appointments, including the reappointment of Glen French as CEO.
Key financial highlights for the quarter include a 15% year-over-year growth in international revenue, contributing to a gross margin of 75%. Despite these gains, the company reported a net loss of $14.0 million, consistent with the previous year’s performance, reflecting ongoing investments in clinical and commercial development.
Looking ahead, Pulmonx projects full-year 2025 revenue to be between $89 million and $90 million, with a gross margin of approximately 73%. The company remains committed to refining its operational strategies to achieve sustainable growth and enhance patient outcomes.